Danks MK, Yoon KJ, Bush RA, Remack JS, Wierdl M, Tsurkan L, Kim SU, Garcia E, Metz MZ, Najbauer J, Potter PM, Aboody KS (2007)
Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma
Cancer Research 67: 22

Aboody KS, Bush RA, Garcia E, Metz MZ, Najbauer J, Justus KA, Phelps DA, Remack JS, Yoon KJ, Gillespie S, Kim SU, Glackin CA, Potter PM, Danks MK (2006)
Development of a tumor-selective approach to treat metastatic cancer
PLoS ONE 1: e23

Yoon KJ, Qi J, Remack JS, Virga KG, Hatfield MJ, Potter PM, Lee RE, Danks MK (2006)
Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy
Mol Cancer Ther 5: 1577

Harel M, Hyatt JL, Brumshtein B, Morton CL, Yoon KJ, Wadkins RM, Silman I, Sussman JL, Potter PM (2005)
The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action
Molecular Pharmacology 67: 1874

Hyatt JL, Tsurkan L, Morton CL, Yoon KJ, Harel M, Brumshtein B, Silman I, Sussman JL, Wadkins RM, Potter PM (2005)
Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11
Chemico-Biological Interactions 157-158: 247

Hyatt JL, Stacy V, Wadkins RM, Yoon KJ, Wierdl M, Edwards CC, Zeller M, Hunter AD, Danks MK, Crundwell G, Potter PM (2005)
Inhibition of carboxylesterases by benzil (diphenylethane-1,2-dione) and heterocyclic analogues is dependent upon the aromaticity of the ring and the flexibility of the dione moiety
Journal of Medicinal Chemistry 48: 5543

Wadkins RM, Hyatt JL, Wei X, Yoon KJ, Wierdl M, Edwards CC, Morton CL, Obenauer JC, Damodaran K, Beroza P, Danks MK, Potter PM (2005)
Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases
Journal of Medicinal Chemistry 48: 2906

Yoon KJ, Potter PM, Danks MK (2005)
Development of prodrugs for enzyme-mediated, tumor-selective therapy
Curr Med Chem Anticancer Agents 5: 107

Wadkins RM, Hyatt JL, Yoon KJ, Morton CL, Lee RE, Damodaran K, Beroza P, Danks MK, Potter PM (2004)
Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity
Molecular Pharmacology 65: 1336

Yoon KJ, Hyatt JL, Morton CL, Lee RE, Potter PM, Danks MK (2004)
Characterization of inhibitors of specific carboxylesterases: development of carboxylesterase inhibitors for translational application
Mol Cancer Ther 3: 903

Yoon KJ, Krull EJ, Morton CL, Bornmann WG, Lee RE, Potter PM, Danks MK (2003)
Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies
Mol Cancer Ther 2: 1171

Yoon KJ, Morton CL, Potter PM, Danks MK, Lee RE (2003)
Synthesis and evaluation of esters and carbamates to identify critical functional groups for esterase-specific metabolism
Bioorganic & Medicinal Chemistry 11: 3237